Savings From Part B Rx Price Substitution Are Small, But Worth Getting – OIG
This article was originally published in The Pink Sheet Daily
HHS Office of Inspector General says CMS’ price substitution policy for drugs exceeding 5% in ASP/AMP pricing differential would have saved Medicare $7 million in 2011, less than a tenth of a percent of total Part B drug spending, CMS does not concur with OIG recommendations to help increase savings.
You may also be interested in...
CMS does not concur with recommendations from the HHS Office of the Inspector General that it should apply its AMP-based price substitution more broadly for drugs reimbursed by Medicare Part B.
“Bona Fide Service Fees” Lawsuit Underscores Need For Care In Distributor Contracts, Medicaid AMP Calculations
Litigation being pursued by former drug wholesale association exec alleges that manufacturers inappropriately classed bona fide service fees as discounts, causing them to report inaccurate average manufacturer prices to CMS.